生物制药公司Arcus Biosciences（股票代码：RCUS）在周四盘后交易中股价大跌5.84%，收于19.05美元。此次下跌主要源于公司宣布了新股发行计划，引发了投资者对潜在股权稀释的担忧。
据悉，Arcus Biosciences正寻求通过股票发行进行融资，但具体发行规模尚未披露。该公司已委托Leerink Partners和高盛担任此次发行的联合账簿管理人。作为一家专注于开发癌症、炎症和自身免疫疾病疗法的生物制药公司，Arcus Biosciences目前拥有约1.08亿股流通股，市值约20亿美元。
尽管股价出现回调，但Arcus Biosciences的市场前景仍然看好。据LSEG数据显示，在13位分析师中，11位给予"强力买入"或"买入"评级，2位给予"持有"评级，目标价中值为29美元，高于一个月前的25美元。值得注意的是，该公司股价年初至今已上涨约36%，显示出较强的市场表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.